2017 – August – Computer science apprentices at AZAD
AZAD Pharmaceutical Ingredients AG now trains computer science apprentices who’ll start their training on 2nd of August and will end in August 2021.
 
2017 - March - AZAD privileges from Armenian Government

Please see the following link to the YouTube video:

Armenian Government provides privileges to AZAD Pharmaceutical Ingredients LLC

2016 - November - Armenia gateway to major markets

Please see the following link to the YouTube video:

ARMENIA GATEWAY TO MAJOR MARKETS

2016 - October - CPhI Barcelona

Thank you very much for visiting us at our booth at CPHI. See you next year in Frankfurt!

ZHAW ZHAW ZHAW

2016 - July - CPhI Barcelona

AZAD Pharma AG and AZAD Pharmaceutical Ingredients AG will attend this year's CPhI in Barcelona in October 2016. We look forward to seeing you there!

2016 - March - second CTI Project

After the successful finalization of the first CTI project the CTI approval committee (Commission for Technology and Innovation) has reviewed a second application and concluded that also this proposed research project qualifies for CTI grant funding for a research and development of new, non-IP protected synthetic route for an API for major depressive disorder treatment.

2015 - December - DCAT
As a DCAT member, AZAD will be attending DCAT in New York City, USA on March 14-17, 2016
2015 - April - CTI Project

AZAD and the Zurich University of Applied Sciences (Zürcher Hochschule für Angewandte Wissenschaften, ZHAW), Wädenswil receive commitment for a Commission for Technology and Innovation (CTI) project.
The CTI has approved the joint proposal of the AZAD and the research group of PD Dr. C.M. Frech at the ZHAW Wädenswil. The project, "Novel, cost-efficient and non-IP protected synthetic route to an Aryl Alkyl-based API" will start on 1 April 2015 and lasts one year.
The project is also published in the „newsletter“ of the ZHAW on page 10:
ZHAW

2015 - February - CPhI Madrid
AZAD Pharma AG and AZAD Pharmaceutical Ingredients AG will attend this year's CPhI in Madrid from 13-15 October 2015. We look forward to seeing you there!
2014 - January - Research using Iron Sucrose AZAD
To answer the EMEA Reflection paper “non-clinical studies for generic nanoparticle medicinal product applications” AZAD commission in vitro and in vivo non-clinical studies to compare the biodistribution and cellular handling of iron sucrose Azad with the original product Venofer®, whereby their properties were found to be essentially similar. These studies have recently been published in peer-reviewed journals, see attachments.

Journal of Pharmacological and Toxicological Methods

Biodistribution and predictive hepatic gene expression of intravenous iron sucrose

Therapeutics for States of Deficiency

Physicochemical and toxicological characterization
of a new generic iron sucrose preparation

Pharmaceutical Development and Technology

Bioavailability and stability of intravenous iron sucrose originator
versus generic iron sucrose AZAD

2013 - October - AZAD successfully completes Phase III trial of generic Brinzolamide ophthalmic suspension

AZAD Pharma sponsored this phase III, multicentre, randomized, investigator-masked, cross-over, comparative efficacy study of its generic Brinzolamide 10mg/ml ophthalmic suspension and Brinzolamide 10mg/ml ophthalmic suspension (Azopt®, Alcon) in open-angle glaucoma and ocular hypertension patients.

The primary objective was to evaluate the efficacy of Brinzolamide 10 mg/ml ophthalmic suspension of Azad Pharma in lowering intraocular pressure (IOP) when compared to Azopt®, Alcon. Secondary objectives were to compare the tolerance of the test (generic) and reference product, and to compare the levels of conjunctival hyperaemia and to evaluate general safety.

Outcome: the IOP reduction and the adverse event profile of the generic Brinzolamide
10 mg/ml ophthalmic suspension of Azad Pharma were shown to be non-inferior to Azopt® (Alcon). It can therefore be concluded that the products are equivalent.
Azad Pharma's Brinzolamide ophthalmic suspension Dossier is now available for out-licensing

2015 - April - CTI Project

AZAD and the Zurich University of Applied Sciences (Zürcher Hochschule für Angewandte Wissenschaften, ZHAW), Wädenswil receive commitment for a Commission for Technology and Innovation (CTI) project.
The CTI has approved the joint proposal of the AZAD and the research group of PD Dr. C.M. Frech at the ZHAW Wädenswil. The project, "Novel, cost-efficient and non-IP protected synthetic route to an Aryl Alkyl-based API" will start on 1 April 2015 and lasts one year.
The project is also published in the „newsletter“ of the ZHAW on page 10:
ZHAW

2015 - February - CPhI Madrid
AZAD Pharma AG and AZAD Pharmaceutical Ingredients AG will attend this year's CPhI in Madrid from 13-15 October 2015. We look forward to seeing you there!
2014 - January - Research using Iron Sucrose AZAD
To answer the EMEA Reflection paper “non-clinical studies for generic nanoparticle medicinal product applications” AZAD commission in vitro and in vivo non-clinical studies to compare the biodistribution and cellular handling of iron sucrose Azad with the original product Venofer®, whereby their properties were found to be essentially similar. These studies have recently been published in peer-reviewed journals, see attachments.

Journal of Pharmacological and Toxicological Methods

Biodistribution and predictive hepatic gene expression of intravenous iron sucrose

Therapeutics for States of Deficiency

Physicochemical and toxicological characterization
of a new generic iron sucrose preparation

Pharmaceutical Development and Technology

Bioavailability and stability of intravenous iron sucrose originator
versus generic iron sucrose AZAD

2013 - October - AZAD successfully completes Phase III trial of generic Brinzolamide ophthalmic suspension

AZAD Pharma sponsored this phase III, multicentre, randomized, investigator-masked, cross-over, comparative efficacy study of its generic Brinzolamide 10mg/ml ophthalmic suspension and Brinzolamide 10mg/ml ophthalmic suspension (Azopt®, Alcon) in open-angle glaucoma and ocular hypertension patients.

The primary objective was to evaluate the efficacy of Brinzolamide 10 mg/ml ophthalmic suspension of Azad Pharma in lowering intraocular pressure (IOP) when compared to Azopt®, Alcon. Secondary objectives were to compare the tolerance of the test (generic) and reference product, and to compare the levels of conjunctival hyperaemia and to evaluate general safety.

Outcome: the IOP reduction and the adverse event profile of the generic Brinzolamide
10 mg/ml ophthalmic suspension of Azad Pharma were shown to be non-inferior to Azopt® (Alcon). It can therefore be concluded that the products are equivalent.
Azad Pharma's Brinzolamide ophthalmic suspension Dossier is now available for out-licensing